{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030662","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.105087+00:00","generated_at":"2026-05-31T10:48:34.483417+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xtant Medical Q2 revenue up 48% to $29.9M; posts positive Adjusted EBITDA of $0.5M","bullets":["Revenue $29.9M, +48% YoY; gross margin 62.1% (+50 bps); net loss $3.9M ($0.03/sh) vs $2.2M loss year ago.","Fifth consecutive quarter of positive Adjusted EBITDA: $0.5M vs $0.1M in prior year quarter.","Launched SimpliGraft and SimpliMax amniotic membrane allografts; added 15 new distributors and 20 IDN contracts in Q2.","Entered $5.0M private placement at $0.64/share on August 7, 2024; cash $5.4M at June 30, 2024.","Reaffirms FY2024 revenue guidance $116M-$120M (27%-31% annual growth)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030662","json":"https://secwatch.observer/filing/0001493152-24-030662.json","markdown":"https://secwatch.observer/filing/0001493152-24-030662.md","text":"https://secwatch.observer/filing/0001493152-24-030662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224030662/0001493152-24-030662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224030662/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:48:34.483417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}